Alu Nucleic Acid Detection for Cell Damage Monitoring

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods lack an efficient, reliable, and inexpensive means to detect genomic DNA released into circulation due to pathophysiological insults such as radiation exposure, infectious agents, or tumorigenesis, making it difficult to identify and differentiate between normal cell aging and disease-related DNA release.

Innovation Solution

The use of free circulating generic biomarkers like Alu sequences, telomeres, and 18S/28S ribosomal RNA sequences in biological samples to indicate cell damage, allowing for the detection and quantification of DNA released into circulation as a result of pathophysiological insults using probe sets and the QuantiGene™ method.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If generic biomarkers (Alu sequences, telomeres, ribosomal RNA) are used to detect cell damage, then detection sensitivity and reliability improve, but the ability to differentiate between normal cell aging and disease-related DNA release deteriorates

Engineering Contradiction:

Improvedetection sensitivityVSAvoiddiscrimination capability

Core Design Contradiction:

Measurement precisionVSLoss of information

Solution Approach 1:

The patent segments the detection approach by using multiple different generic biomarkers (Alu sequences, telomeres, ribosomal RNA) rather than relying on a single marker. This segmentation allows the system to maintain high detection sensitivity while the combination of markers provides better discrimination capability, as different markers may be released at different rates or in different patterns under normal aging versus pathological conditions.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent applies universality by using generic biomarkers that serve multiple functions: they can detect various types of cell damage (radiation, infection, tumorigenesis, chemical exposure) and can be measured using a single standardized assay platform (QuantiGene™). This multi-functionality improves detection reliability across different disease states while the universal nature of these markers allows for standardized measurement that enhances sensitivity.

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Reliability

If current nucleic acid detection methods are used, then tumor specific markers can be detected, then detection specificity improves, but detection sensitivity in early disease stages deteriorates due to low marker amounts

Engineering Contradiction:

Improvedetection specificityVSAvoiddetection sensitivity

Core Design Contradiction:

ReliabilityVSMeasurement precision

Solution Approach 1:

The patent uses generic biomarkers as intermediaries to detect cell damage in early disease stages. Instead of directly detecting tumor-specific markers which are present in low amounts, the assay detects generic biomarkers (Alu sequences, telomeres, ribosomal RNA) that are released in larger quantities during cell damage. These intermediaries serve as reliable indicators of cellular stress and damage, providing both sensitivity for early detection and reliability for confirming pathological processes.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent employs preliminary action by detecting generic biomarkers that are released early in the cell damage process, before tumor-specific markers accumulate to detectable levels. This preliminary detection of generic markers allows for early identification of individuals with ongoing cell damage, enabling intervention before the disease progresses to a stage where tumor-specific markers would be reliably detectable.

Inventive Principle:

Principle #10Preliminary action

3Ease of manufacture

If no specific biomarkers are available, then detection cost is reduced, but detection reliability deteriorates due to inability to distinguish pathological from normal DNA release

Engineering Contradiction:

Improvedetection costVSAvoiddetection accuracy

Core Design Contradiction:

Ease of manufactureVSReliability

Solution Approach 1:

The patent achieves cost-effectiveness through universality by using a single standardized assay platform (QuantiGene™) that can detect multiple different generic biomarkers (Alu sequences, telomeres, ribosomal RNA). This universal approach eliminates the need for developing and validating multiple separate assays for different markers, significantly reducing detection costs. Simultaneously, the ability to measure multiple markers with one platform enhances reliability by providing comprehensive assessment of cell damage through the combined information from different biomarker patterns.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach enables the reliable detection and monitoring of cell damage associated with various pathophysiological insults, including radiation exposure and disease states, providing a sensitive and specific method for identifying exposed individuals and tracking treatment effects.

Implementation Method 1

Methodology Applied

Scientific EffectNucleic acid hybridization:

Data Source

PatentUS8404444B2Method for predicting the level of damage to cells by measuring free circulating Alu nucleic acid

Publication Date: 2013.03.26 DIACARTA LTD

AI summary

This invention relates generally to methods for detecting cell damage as a consequence of pathophysiological or traumatic insults such as in a nuclear accident, bioterror attack, tumorigenesis, infections or in individuals with cardiovascular disease.